JP2019504877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504877A5 JP2019504877A5 JP2018553042A JP2018553042A JP2019504877A5 JP 2019504877 A5 JP2019504877 A5 JP 2019504877A5 JP 2018553042 A JP2018553042 A JP 2018553042A JP 2018553042 A JP2018553042 A JP 2018553042A JP 2019504877 A5 JP2019504877 A5 JP 2019504877A5
- Authority
- JP
- Japan
- Prior art keywords
- particles
- composition
- carrier
- antigens
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 238000000034 method Methods 0.000 claims 9
- 239000004793 Polystyrene Substances 0.000 claims 6
- 229920001983 poloxamer Polymers 0.000 claims 6
- 229920002223 polystyrene Polymers 0.000 claims 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- 239000004743 Polypropylene Substances 0.000 claims 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 3
- 229960000502 poloxamer Drugs 0.000 claims 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- -1 polypropylene Polymers 0.000 claims 3
- 229920001155 polypropylene Polymers 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 238000007334 copolymerization reaction Methods 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000002641 enzyme replacement therapy Methods 0.000 claims 1
- 230000000521 hyperimmunizing effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000009163 protein therapy Methods 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022125126A JP7586863B2 (ja) | 2015-12-23 | 2022-08-04 | 共有ポリマー抗原コンジュゲート化粒子 |
| JP2024195011A JP2025060584A (ja) | 2015-12-23 | 2024-11-07 | 共有ポリマー抗原コンジュゲート化粒子 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387183P | 2015-12-23 | 2015-12-23 | |
| US62/387,183 | 2015-12-23 | ||
| US201662292098P | 2016-02-05 | 2016-02-05 | |
| US62/292,098 | 2016-02-05 | ||
| PCT/US2016/068423 WO2017112899A1 (en) | 2015-12-23 | 2016-12-22 | Covalent polymer-antigen conjugated particles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022125126A Division JP7586863B2 (ja) | 2015-12-23 | 2022-08-04 | 共有ポリマー抗原コンジュゲート化粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504877A JP2019504877A (ja) | 2019-02-21 |
| JP2019504877A5 true JP2019504877A5 (enExample) | 2020-02-06 |
| JP7194593B2 JP7194593B2 (ja) | 2022-12-22 |
Family
ID=59091248
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553042A Active JP7194593B2 (ja) | 2015-12-23 | 2016-12-22 | 共有ポリマー抗原コンジュゲート化粒子 |
| JP2022125126A Active JP7586863B2 (ja) | 2015-12-23 | 2022-08-04 | 共有ポリマー抗原コンジュゲート化粒子 |
| JP2024195011A Pending JP2025060584A (ja) | 2015-12-23 | 2024-11-07 | 共有ポリマー抗原コンジュゲート化粒子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022125126A Active JP7586863B2 (ja) | 2015-12-23 | 2022-08-04 | 共有ポリマー抗原コンジュゲート化粒子 |
| JP2024195011A Pending JP2025060584A (ja) | 2015-12-23 | 2024-11-07 | 共有ポリマー抗原コンジュゲート化粒子 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11510996B2 (enExample) |
| EP (1) | EP3393514A4 (enExample) |
| JP (3) | JP7194593B2 (enExample) |
| KR (1) | KR102822161B1 (enExample) |
| AU (1) | AU2016379413B2 (enExample) |
| CA (1) | CA3008892A1 (enExample) |
| IL (1) | IL260074B1 (enExample) |
| WO (1) | WO2017112899A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108117586A (zh) | 2010-08-10 | 2018-06-05 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| EP2841098A4 (en) | 2012-04-23 | 2016-03-02 | Allertein Therapeutics Llc | NANOPARTICLES FOR THE TREATMENT OF ALLERGIES |
| EP3760223A1 (en) | 2013-04-03 | 2021-01-06 | N-Fold Llc | Nanoparticle composition for desensitizing a subject to peanut allergens |
| AU2015233084B2 (en) | 2014-02-21 | 2020-12-17 | Anokion Sa | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US11510996B2 (en) * | 2015-12-23 | 2022-11-29 | Cour Pharmaceuticals Development Company Inc. | Covalent polymer-antigen conjugated particles |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| WO2019157282A1 (en) * | 2018-02-08 | 2019-08-15 | Cour Pharmaceuticals Development Company Inc. | Treatment of celiac disease with tolerizing particles |
| CN112384239A (zh) | 2018-05-09 | 2021-02-19 | 芝加哥大学 | 影响免疫耐受的组合物和方法 |
| WO2019217780A1 (en) | 2018-05-11 | 2019-11-14 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
| CN113166241B (zh) | 2018-08-16 | 2025-02-25 | 约翰霍普金斯大学 | 人类znt8抗体 |
| CA3149308A1 (en) * | 2019-07-31 | 2021-02-04 | Oncour Pharma, Inc. | Treatment of immune evasive tumors |
| GB201913408D0 (en) * | 2019-09-17 | 2019-10-30 | King S College London | Proinsulin peptides for type 1 diabetes |
| US12366570B2 (en) | 2019-10-01 | 2025-07-22 | The Johns Hopkins University | Cell-based ZNT8 assay |
| WO2022032290A2 (en) * | 2020-08-05 | 2022-02-10 | University Of Maryland, Baltimore | Engineering diverse antigen-presenting cells to control antigen-specific responses |
| CN112057425A (zh) * | 2020-09-30 | 2020-12-11 | 严鹏科 | 一种雷帕霉素制剂及其制备方法 |
| IL307688A (en) * | 2021-04-16 | 2023-12-01 | Cour Pharmaceuticals Dev Company Inc | Treatment of peanut allergy with tolerizing nanoparticles |
| JP2024518277A (ja) | 2021-04-16 | 2024-05-01 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 免疫寛容の維持を追跡する方法 |
| IL312097A (en) | 2021-10-21 | 2024-06-01 | Cour Pharmaceuticals Dev Company Inc | Treatment of primary biliary cirrhosis (PBC) with tolerable nanoparticles |
| EP4514320A1 (en) * | 2022-04-29 | 2025-03-05 | Cour Pharmaceuticals Development Company Inc. | Tolerizing immune modifying nanoparticles for overcoming the immunogenicity of therapeutic vectors and proteins |
| CA3263470A1 (en) | 2022-07-29 | 2024-02-01 | Repertoire Immune Medicines, Inc. | T-LYMPHOCYTE EPITOPES ASSOCIATED WITH TYPE 1 DIABETES |
| JP2025536294A (ja) | 2022-10-19 | 2025-11-05 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 寛容化ナノ粒子でのピーナッツアレルギーの治療 |
| KR20250162851A (ko) * | 2023-03-24 | 2025-11-19 | 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. | 중증 근무력증 치료를 위한 관용화 면역 변형 나노입자 |
| WO2024243410A1 (en) | 2023-05-23 | 2024-11-28 | Cour Pharmaceuticals Development Company Inc. | Preparation of tolerizing nanoparticles for the treatment of primary biliary cholangitis |
| TW202500576A (zh) | 2023-05-25 | 2025-01-01 | 美商庫爾製藥發展公司股份有限公司 | 以免疫耐受性(tolerizing)奈米粒子治療1型糖尿病(t1d) |
| WO2025072849A1 (en) | 2023-09-29 | 2025-04-03 | Repertoire Immune Medicines, Inc. | Mhc-presentable peptides associated with type 1 diabetes |
| WO2025199149A1 (en) * | 2024-03-18 | 2025-09-25 | Cour Pharmaceuticals Development Company Inc. | Sting agonism for antigen specific tolerance |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JP3712260B2 (ja) | 1992-02-28 | 2005-11-02 | オートイミューン インク | 自己免疫疾患のバイスタンダー抑制 |
| AU674584B2 (en) | 1993-06-02 | 1997-01-02 | Tvw Telethon Institute For Child Health Research | Cryptic peptides for use in inducing immunologic tolerance |
| DE69818052T2 (de) | 1997-03-31 | 2004-07-08 | The Regents Of The University Of Michigan, Ann Arbor | Offenporige bioabbaubare matrize |
| US7427602B1 (en) | 1998-05-13 | 2008-09-23 | The Regents Of The University Of Michigan | Sustained DNA delivery from structural matrices |
| US6890556B1 (en) | 2001-02-14 | 2005-05-10 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
| US7029697B2 (en) | 2001-02-14 | 2006-04-18 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
| US7846466B2 (en) | 2004-06-10 | 2010-12-07 | Northwestern University | Biodegradable scaffolds and uses thereof |
| EP2256130B1 (en) | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Novel insulin derivatives |
| EP2620157A3 (en) * | 2007-10-12 | 2013-10-16 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| US20090238879A1 (en) | 2008-01-24 | 2009-09-24 | Northwestern University | Delivery scaffolds and related methods of use |
| US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| MX346450B (es) | 2008-11-30 | 2017-03-17 | Immusant Inc * | Composiciones y métodos para el tratamiento de la enfermedad celíaca. |
| JP2012515722A (ja) | 2009-01-20 | 2012-07-12 | ノースウェスタン ユニバーシティ | 抗原特異的寛容の誘導のための組成物および方法 |
| KR20220166879A (ko) | 2012-06-21 | 2022-12-19 | 노쓰웨스턴유니버시티 | 펩티드 접합된 입자 |
| MX372849B (es) | 2013-08-13 | 2020-07-06 | Univ Northwestern | Partículas conjugadas con péptidos. |
| US11510996B2 (en) * | 2015-12-23 | 2022-11-29 | Cour Pharmaceuticals Development Company Inc. | Covalent polymer-antigen conjugated particles |
-
2016
- 2016-12-22 US US16/064,528 patent/US11510996B2/en active Active
- 2016-12-22 EP EP16880118.1A patent/EP3393514A4/en active Pending
- 2016-12-22 CA CA3008892A patent/CA3008892A1/en active Pending
- 2016-12-22 AU AU2016379413A patent/AU2016379413B2/en active Active
- 2016-12-22 WO PCT/US2016/068423 patent/WO2017112899A1/en not_active Ceased
- 2016-12-22 KR KR1020187020952A patent/KR102822161B1/ko active Active
- 2016-12-22 IL IL260074A patent/IL260074B1/en unknown
- 2016-12-22 JP JP2018553042A patent/JP7194593B2/ja active Active
-
2022
- 2022-08-04 JP JP2022125126A patent/JP7586863B2/ja active Active
- 2022-10-24 US US18/049,136 patent/US12502436B2/en active Active
-
2024
- 2024-11-07 JP JP2024195011A patent/JP2025060584A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504877A5 (enExample) | ||
| Drachuk et al. | pH-responsive layer-by-layer nanoshells for direct regulation of cell activity | |
| Tomaro-Duchesneau et al. | Microencapsulation for the therapeutic delivery of drugs, live mammalian and bacterial cells, and other biopharmaceutics: current status and future directions | |
| Li et al. | Core–shell supramolecular gelatin nanoparticles for adaptive and “on-demand” antibiotic delivery | |
| Cu et al. | Controlled surface modification with poly (ethylene) glycol enhances diffusion of PLGA nanoparticles in human cervical mucus | |
| Wang et al. | More effective nanomedicines through particle design | |
| Wong et al. | Modulating antimicrobial activity and mammalian cell biocompatibility with glucosamine-functionalized star polymers | |
| Yang et al. | Nanoparticle penetration of human cervicovaginal mucus: The effect of polyvinyl alcohol | |
| Park et al. | Lipid-hydrogel-nanostructure hybrids as robust biofilm-resistant polymeric materials | |
| Sterling et al. | Murine and non-human primate dendritic cell targeting nanoparticles for in vivo generation of regulatory T-cells | |
| Zheng et al. | Enhancement of surface graft density of MPEG on alginate/chitosan hydrogel microcapsules for protein repellency | |
| Tang et al. | Physical hydrogels with self-assembled nanostructures as drug delivery systems | |
| Wu et al. | Tumor‐Acidity Activated Surface Charge‐Conversion of Polymeric Nanocarriers for Enhanced Cell Adhesion and Targeted Drug Release | |
| MX350501B (es) | Nanotecnologia de vacuna. | |
| CN105327353B (zh) | 一种模拟超氧化物歧化酶/过氧化氢酶的纳米药物、制备方法及其应用 | |
| Pan et al. | Amino-modified polymer nanoparticles as adjuvants to activate the complement system and to improve vaccine efficacy in vivo | |
| JP2018503736A5 (enExample) | ||
| Giovagnoli et al. | Alginates in pharmaceutics and biomedicine: is the future so bright? | |
| Richardson et al. | Thermally induced charge reversal of layer-by-layer assembled single-component polymer films | |
| Mudhakir et al. | Encapsulation of risperidone into chitosan-based nanocarrier via ionic binding interaction | |
| Luc et al. | Antifouling properties of amine-oxide-containing zwitterionic polymers | |
| Vorobii et al. | Antifouling microparticles to scavenge lipopolysaccharide from human blood plasma | |
| WO2022027829A1 (zh) | 用于多特异性抗体递送的蛋白型纳米颗粒及其应用、制备方法 | |
| US8586095B2 (en) | Thermosensitive nanostructure for hyperthermia treatment | |
| Lu et al. | Preparation and characterization of molecularly imprinted poly (hydroxyethyl methacrylate) microspheres for sustained release of gatifloxacin |